Logging in to Dialog Trying 31060000009999...Open DIALOG INFORMATION SERVICES PLEASE LOGON: ****** ENTER PASSWORD: ***** Welcome to DIALOG Dialog level 02.14.01D Last logoff: 17mar03 15:34:45 Logon file001 17may03 13:29:29 * * * * See HELP NEWS 225 for information on new search prefixes and display codes * * * * * * File 1:ERIC 1966-2003/Apr 23 (c) format only 2003 The Dialog Corporation Set Items Description - - - - - Cost is in DialUnits ? b 410 17may03 13:29:29 User208652 Session D492.1 \$0.26 0.074 DialUnits File1 \$0.26 Estimated cost File1 \$0.26 Estimated cost this search \$0.26 Estimated total session cost 0.074 DialUnits File 410:Chronolog(R) 1981-2003/Mar (c) 2003 The Dialog Corporation Set Items Description _ _ _ - - - - -? set hi ;set hi HILIGHT set on as '' HILIGHT set on as '' ? b 411 17may03 13:29:49 User208652 Session D492.2 \$0.00 0.070 DialUnits File410 \$0.00 Estimated cost File410 \$0.07 TELNET \$0.07 Estimated cost this search \$0.33 Estimated total session cost 0.144 DialUnits File 411:DIALINDEX(R) DIALINDEX(R) (c) 2003 The Dialog Corporation plc *** DIALINDEX search results display in an abbreviated *** *** format unless you enter the SET DETAIL ON command. *** ? sf allbiosci You have 73 files in your file list. (To see banners, use SHOW FILES command) ? s prothymosin(15n)(endometrium or endometriosis or uter???)

Connecting via Winsock to Dialog

```
Your SELECT statement is:
   s prothymosin(15n)(endometrium or endometriosis or uter???)
           Items File
       Examined 50 files
               1 357: Derwent Biotech Res. 1982-2003/May W2
                   399: CA SEARCH(R)_1967-2003/UD=13820
   2 files have one or more items; file list includes 73 files.
? save temp endomet
>>>Name ENDOMET has more than 6 characters
Temp SearchSave "TD003" stored
? b n1:n2
>>>You must first use the RANK FILES command (RF)
Your last SELECT statement was:
   S PROTHYMOSIN(15N) (ENDOMETRIUM OR ENDOMETRIOSIS OR UTER???)
Ref
                  File
           Items
_ _ _
N1
               1
                  357: Derwent Biotech Res. 1982-2003/May W2
N2
                   399: CA SEARCH(R)_1967-2003/UD=13820
N3
               Ω
                    2: INSPEC_1969-2003/May W1
N4
               0
                     5: Biosis Previews(R)_1969-2003/May W2
                     6: NTIS 1964-2003/May W3
N5
               0
N6
               0
                     8: Ei Compendex(R)_1970-2003/May W1
N7
               0
                    10: AGRICOLA_70-2003/May
                    29: Meteor. & Geoastro. Abs. 1970-2002/Jul
N8
Ν9
               0
                    31: World Surface Coatings Abs_1976-2003/Apr
N10
               0
                   34: SciSearch(R) Cited Ref Sci 1990-2003/May W2
   2 files have one or more items; file list includes 73 files.
        - Enter P or PAGE for more -
? b n1:n2
       17may03 13:33:52 User208652 Session D492.3
            $1.41 0.705 DialUnits File411
     $1.41 Estimated cost File411
     $1.16 TELNET
     $2.57 Estimated cost this search
     $2.90 Estimated total session cost 0.849 DialUnits
SYSTEM:OS - DIALOG OneSearch
 File 357:Derwent Biotech Res. _1982-2003/May W2 (c) 2003 Thomson Derwent & ISI
*File 357: File is now current. See HELP NEWS 357.
Alert feature enhanced for multiple files, etc. See HELP ALERT.
 File 399:CA SEARCH(R) 1967-2003/UD=13820
         (c) 2003 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.
      Set Items Description
      ___ ___
? exs
Executing TD003
Hilight option is not available in file(s) 399
HILIGHT set on as '%'
           251 PROTHYMOSIN
8042 ENDOMETRIUM
1466 ENDOMETRIOSIS
           42241 UTER???
              2 PROTHYMOSIN(15N)(ENDOMETRIUM OR ENDOMETRIOSIS OR UTER???)
      S1
? t 1/5/all
```

```
(Item 1 from file: 357)
DIALOG(R) File 357: Derwent Biotech Res.
(c) 2003 Thomson Derwent & ISI. All rts. reserv.
0249290 DBR Accession No.: 2000-03780
                                             PATENT
Diagnosis and treatment of %endometriosis% using %prothymosin% and
     %prothymosin% specific binding agents - protein detection method using
    DNA probe for disease diagnosis, prognosis, therapy and antisense
    oligonucleotide for gene therapy
AUTHOR: Schneider P A; French C K; Yamamoto K K
CORPORATE SOURCE: Irvine, CA, USA.
PATENT ASSIGNEE: Reprogen 1999
PATENT NUMBER: WO 9963116 PATENT DATE: 19991209 WPI ACCESSION NO.:
2000-086987 (2007)
PRIORITY APPLIC. NO.: US 88016 APPLIC. DATE: 19980604
NATIONAL APPLIC. NO.: WO 99US12336 APPLIC. DATE: 19990603
LANGUAGE: English
ABSTRACT: A method (I) for diagnosing %endometriosis%, which consists of
    detecting elevated levels of %prothymosin% gene product in a sample, is
     new. Also claimed are: a method for monitoring the progress of
     %endometriosis% by comparing the amount of %prothymosin% in 2 test
    samples, taken from the same patient at different times; a kit for
                  %prothymosin% and/or diagnosing %endometriosis% which
      detecting
     consists of a compound that binds a *prothymosin* gene product; the diagnosis of *endometriosis* by detecting the presence of a
      *prothymosin* gene product in *endometriosis* tissue from a subject in
      vivo; a method for treating %endometriosis% which involves
    administering a DNA probe which consists of a detectable label and a
               that specifically binds
                                              prothymosin, identifying an
    endometriotic lesion in situ by locating the bound label and excising
    the lesion; a method for screening for compounds that modulate the expression of %prothymosin% in an endometrial cell; and treating
       %endometriosis% by administering a compound which decreases
     $prothymosin% activity. The above may be useful to diagnose, prognose
      and treat %endometriosis% and antisense
                                                            %prothymosin%
    oligonucleotides may be used in gene therapy. (58pp)
DESCRIPTORS: %prothymosin% det. method, DNA probe, antisense
    oligonucleotide, appl. %endometriosis% diagnosis, prognosis, therapy,
    gene therapy DNA sequence protein sequence DNA hybridization (Vol.19,
    No.7)
SECTION: PHARMACEUTICALS-Clinical Genetic Techniques; GENETIC ENGINEERING
    AND FERMENTATION-Nucleic Acid Technology (D7,A1)
            (Item 1 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.
  132021878
                CA: 132(3)21878b
                                     PATENT
  Use of prothymosin in the diagnosis and treatment of endometriosis
  INVENTOR (AUTHOR): Schneider, Patrick A.; French, Cynthia K.; Yamamoto,
Karen K.
  LOCATION: USA
  ASSIGNEE: Reprogen, Inc.
  PATENT: PCT International; WO 9963116 A2 DATE: 19991209
  APPLICATION: WO 99US12336 (19990603) *US 88016 (19980604)
  PAGES: 59 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/68A;
G01N-033/53B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR;
BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID;
IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
  DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; UG; ZW; AT; BE; CH;
CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG;
```

CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG SECTION: CA214013 Mammalian Pathological Biochemistry CA201XXX Pharmacology CA206XXX General Biochemistry IDENTIFIERS: prothymosin endometriosis diagnosis therapy drug screening DESCRIPTORS: Peritoneum... administration of diagnostic probe into; use of prothymosin in the diagnosis and treatment of endometriosis Immunoassay... competitive, use in diagnosis; use of prothymosin in the diagnosis and treatment of endometriosis Vagina... diagnostic sample comprising fluid from; use of prothymosin in the diagnosis and treatment of endometriosis Ascitic fluid... Blood... Urine... diagnostic sample comprising; use of prothymosin in the diagnosis and treatment of endometriosis Phosphorothioate oligonucleotides... Primers (nucleic acid)... diagnostic use; use of prothymosin in the diagnosis and treatment of endometriosis cDNA... DNA... Gene, animal... mRNA... RNA... encoding prothymosin; use of prothymosin in the diagnosis and treatment of endometriosis Uterus,disease... endometriosis; use of prothymosin in the diagnosis and treatment of endometriosis endometrium, diagnostic sample comprising ectopic and/or eutopic tissue from; use of prothymosin in the diagnosis and treatment of endometriosis Drug screening... for compds. that regulate prothymosin expression/activity; use of prothymosin in the diagnosis and treatment of endometriosis Test kits... for detection of prothymosin; use of prothymosin in the diagnosis and treatment of endometriosis Radiation detectors... Geiger, use in diagnosis; use of prothymosin in the diagnosis and treatment of endometriosis immobilized, encoding prothymosin; use of prothymosin in the diagnosis and treatment of endometriosis Diagnosis... immunodiagnosis; use of prothymosin in the diagnosis and treatment of endometriosis Oligonucleotides... labeled, diagnostic use; use of prothymosin in the diagnosis and treatment of endometriosis Diagnosis... mol.; use of prothymosin in the diagnosis and treatment of endometriosis Imaging... NMR, use in diagnosis; use of prothymosin in the diagnosis and treatment of endometriosis Immunoassay... non-competitive, use in diagnosis; use of prothymosin in the diagnosis and treatment of endometriosis Peptide nucleic acids... oligonucleotides comprising, diagnostic use; use of prothymosin in the

solns., i.p., administration of drugs via; use of prothymosin in the

diagnosis and treatment of endometriosis

diagnosis and treatment of endometriosis

Drug delivery systems...

```
Drugs...
    that regulate prothymosin expression/activity; use of prothymosin in
    the diagnosis and treatment of endometriosis
Mass spectrometry...
    use in detecting prothymosin; use of prothymosin in the diagnosis and
    treatment of endometriosis
Antibodies... Cameras... Nucleic acid amplification (method)... Paramagnetic
materials... Radionuclides...
    use in diagnosis; use of prothymosin in the diagnosis and treatment of
    endometriosis
Antisense DNA... Ribozymes...
    use in regulating prothymosin expression; use of prothymosin in the
    diagnosis and treatment of endometriosis
    use of prothymosin in the diagnosis and treatment of endometriosis
Nucleotides, uses...
    2'-O-methyl; oligonucleotides comprising; use of prothymosin in the
    diagnosis and treatment of endometriosis
  CAS REGISTRY NUMBERS:
993-13-5 22638-09-1 41744-81-4 oligonucleotides comprising, diagnostic
    use; use of prothymosin in the diagnosis and treatment of endometriosis
251922-35-7 251922-36-8 251922-37-9 unclaimed nucleotide sequence; use
    of prothymosin in the diagnosis and treatment of endometriosis
125524-66-5 unclaimed protein sequence; use of prothymosin in the
    diagnosis and treatment of endometriosis
89964-14-7P use of prothymosin in the diagnosis and treatment of
    endometriosis
? b 411
       17may03 13:36:48 User208652 Session D492.4
            $1.61 0.090 DialUnits File357
               $3.23 1 Type(s) in Format 5
            $3.23 1 Types
     $4.84
            Estimated cost File357
            $2.75 1 Types
     $4.81
           Estimated cost File399
           OneSearch, 2 files, 0.254 DialUnits FileOS
    $0.70
    $10.35 Estimated cost this search
    $13.25 Estimated total session cost 1.103 DialUnits
File 411:DIALINDEX(R)
DIALINDEX (R)
   (c) 2003 The Dialog Corporation plc
*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***
? sf allmedph
  You have 169 files in your file list.
   (To see banners, use SHOW FILES command)
? s prothymosin(9n)(endometrium or endometriosis or uterus or uterine)
Your SELECT statement is:
   s prothymosin(9n)(endometrium or endometriosis or uterus or uterine)
          Items File
           ----
      Examined 50 files
                  348: EUROPEAN PATENTS_1978-2003/Apr W04
              2
                  349: PCT FULLTEXT 1979-2002/UB=20030515,UT=20030508
      Examined 100 files
                  357: Derwent Biotech Res. __1982-2003/May W2
              1
                  399: CA SEARCH(R)_1967-2003/UD=13820
```

Examined 150 files

```
4 files have one or more items; file list includes 169 files.
Your last SELECT statement was:
   S PROTHYMOSIN(9N) (ENDOMETRIUM OR ENDOMETRIOSIS OR UTERUS OR UTERINE)
           Items
                   File
_ - -
           ----
                   349: PCT FULLTEXT 1979-2002/UB=20030515,UT=20030508
N1
N2
                   348: EUROPEAN PATENTS_1978-2003/Apr W04
                   357: Derwent Biotech Res. 1982-2003/May W2
N4
                   399: CA SEARCH(R) 1967-2003/UD=13820
                    1: ERIC_1966-2003/Apr 23
N5
               0
Ν6
               0
                    2: INSPEC_1969-2003/May W1
N7
               0
                     5: Biosis Previews(R)_1969-2003/May W2
N8
               0
                     6: NTIS 1964-2003/May W3
                     7: Social SciSearch(R)_1972-2003/May W2
N 9
               0
N10
               0
                     8: Ei Compendex(R)_1970-2003/May W1
   4 files have one or more items; file list includes 169 files.
        - Enter P or PAGE for more -
? b n1:n4
       17may03 13:38:54 User208652 Session D492.5
            $1.86
                     0.932 DialUnits File411
     $1.86 Estimated cost File411
     $0.70 TELNET
     $2.56 Estimated cost this search
    $15.81 Estimated total session cost
                                            2.036 DialUnits
SYSTEM:OS - DIALOG OneSearch
  File 349:PCT FULLTEXT 1979-2002/UB=20030515,UT=20030508
         (c) 2003 WIPO/Univentio
  File 348:EUROPEAN PATENTS 1978-2003/Apr W04
         (c) 2003 European Patent Office
  File 357:Derwent Biotech Res. _1982-2003/May W2 (c) 2003 Thomson Derwent & ISI
*File 357: File is now current. See HELP NEWS 357.
Alert feature enhanced for multiple files, etc. See HELP ALERT.
  File 399:CA SEARCH(R) 1967-2003/UD=13820
         (c) 2003 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.
      Set Items Description
? s PROTHYMOSIN(9N)(ENDOMETRIUM OR ENDOMETRIOSIS OR UTERUS OR UTERINE)
             344 PROTHYMOSIN
           10276 ENDOMETRIUM
            3893
                  ENDOMETRIOSIS
           48607 UTERUS
           16857 UTERINE
      S1
                  PROTHYMOSIN(9N) (ENDOMETRIUM OR ENDOMETRIOSIS OR UTERUS OR
                  UTERINE)
? t 1/5/all
 1/5/1
           (Item 1 from file: 349)
DIALOG(R) File 349: PCT FULLTEXT
(c) 2003 WIPO/Univentio. All rts. reserv.
           **Image available**
RIBOZYME BASED TREATMENT OF FEMALE REPRODUCTIVE DISEASES
MODULATION A BASE DE L'ACIDE NUCLEIQUE DES MALADIES ET TROUBLES DE
    L'APPAREIL REPRODUCTEUR CHEZ LA FEMME
Patent Applicant/Assignee:
```

RIBOZYME PHARMACEUTICALS INCORPORATED, 2950 Wilderness Place, Boulder, CO 80301, US, US (Residence), US (Nationality), (For all designated states except: US) CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA 94608-2916, US, US (Residence), US (Nationality), (For all designated states except: US) Patent Applicant/Inventor: ESCOBEDO Jaime, 1470 Livorna Road, Alamo, CA 94507, US, US (Residence), US (Nationality), (Designated only for: US) MCSWIGGEN James, 4866 Franklin Drive, Boulder, CO 80301, US, US (Residence), US (Nationality), (Designated only for: US) PAVCO Pamela, 705 Barberry Circle, Lafayette, CO 80026, US, US (Residence), US (Nationality), (Designated only for: US) STINCHCOMB Dan, 8409 South Country Road 3, Ft. Collins, CO 80528, US, US (Residence), US (Nationality), (Designated only for: US) SANDBERG Jennifer, 620 Bluegrass Drive, Longmont, CO 80503, US, US (Residence), US (Nationality), (Designated only for: US) GORDON Gilad, 3605 Silver Plume Lane, Boulder, CO 80303, US, US (Residence), US (Nationality), (Designated only for: US) Legal Representative: TERPSTRA Anita J (agent), McDonnell Boehnen Hulbert & Berghoff, Suite 3200, 300 South Wacker Drive, Chicago, IL 60606, US, Patent and Priority Information (Country, Number, Date): Patent: WO 200296927 A2-A3 20021205 (WO 0296927) Application: WO 2002US17674 20020529 (PCT/WO US0217674) Priority Application: US 2001870161 20010529; US 2001334461 20011130; US 2002138674 20020503 Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW (EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR (OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG (AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW (EA) AM AZ BY KG KZ MD RU TJ TM Main International Patent Class: C07H-021/04 International Patent Class: C12Q-001/68; C12N-005/00 Publication Language: English Filing Language: English Fulltext Availability: Detailed Description Claims Fulltext Word Count: 67234

English Abstract

The present invention relates to nucleic acid molecules, including dsRNA, siRNA, antisense, 2,5-A chimeras, aptamers, and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, and allozymes, which modulate the expression of vascular endothelial growth factor receptor (VEGF) and/or vascular endothelial growth factor receptor (VEGFr) genes for the treatment and/or diagnosis of diseases and conditions associated with angiogenesis, such as cancer, tumor angiogenesis, or ocular indications such as diabetic retinopathy, or age related macular degeneration, proliferative diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis, psoriasis, wound healing, and female reproductive disorders and conditions, including but not limited to endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.

French Abstract

La presente invention porte sur des molecules d'acide nucleique comprenant l'ARNds, l'ARNsi, un antisens, des chimeres 2,5-A, des aptameres et des molecules enzymatiques de l'acide nucleique telles que des ribozymes a tete de marteau, des DNAzymes et des allozymes qui modulent l'expression du recepteur du facteur de croissance vasculaire

et/ou des genes du recepteur du facteur de croissance endothelial et utiles dans le traitement et/ou le diagnostic de maladies et etats associes a l'angiogenese tels que le cancer, l'angiogenese tumorale ou des indications oculaires telles que la retinopathie diabetique ou la degenerescence maculaire due a l'age, la retinopathie diabetique proliferative, l'angiogenese induite par l'hypoxie, l'arthrite rhumatoide, le psoriasis, la cicatrisation des lesions et les troubles et etats de l'appareil reproducteur feminin, ces etats comprenant, mais pas exclusivement, l'endometriose, le carcinome de l'endometre, les troubles de saignement gynecologiques, l'irregularite menstruelle, l'ovulation, le syndrome premenstruel et le dysfonctionnement menopausique.

Legal Status (Type, Date, Text)

Publication 20021205 A2 Without international search report and to be republished upon receipt of that report.

Search Rpt 20030220 Late publication of international search report Republication 20030220 A3 With international search report.

1/5/2 (Item 2 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2003 WIPO/Univentio. All rts. reserv.

00531764

USE OF %PROTHYMOSIN% IN THE DIAGNOSIS AND TREATMENT OF %ENDOMETRIOSIS% UTILISATION DE LA PROTHYMOSINE DANS LE DIAGNOSTIC ET LE TRAITEMENT DE L'ENDOMETRIOSE

Patent Applicant/Assignee:

REPROGEN INC,

SCHNEIDER Patrick A,

FRENCH Cynthia K,

YAMAMOTO Karen K,

Inventor(s):

SCHNEIDER Patrick A,

FRENCH Cynthia K,

YAMAMOTO Karen K,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9963116 A2 19991209 Application: WO 99US12336 19990603

WO 99US12336 19990603 (PCT/WO US9912336)

Priority Application: US 9888016 19980604

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

Main International Patent Class: C12Q-001/68

International Patent Class: G01N-033/53

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 18704

English Abstract

Prothymosin expression is up-regulated in endometriotic tissue. This invention provides methods of diagnosing %endometriosis% by detecting up-regulation of a %prothymosin% gene product, and methods of treating %endometriosis% by down-regulating expression of %prothymosin% in ectopic or eutopic endometriotic tissue.

French Abstract

Selon cette invention, on regule positivement l'expression de la prothymosine dans un tissu endometrial. L'invention concerne des procedes de diagnostic de l'endometriose par la detection de regulation positive

d'un produit genique de prothymosine ainsi que des procedes pour traiter l'endometriose par la regulation negative de l'expression de prothymosine dans un tissu endometrial ectopique ou eutopique.

```
1/5/3
           (Item 1 from file: 348)
DIALOG(R) File 348: EUROPEAN PATENTS
(c) 2003 European Patent Office. All rts. reserv.
01116587
USE OF %PROTHYMOSIN% IN THE DIAGNOSIS AND TREATMENT OF %ENDOMETRIOSIS%
VERWENDUNG VON PROTHYMOSIN ZUR DIAGNOSE UND BEHANDLUNG VON ENDOMETRIOSE
UTILISATION DE LA PROTHYMOSINE DANS LE DIAGNOSTIC ET LE TRAITEMENT DE
    L'ENDOMETRIOSE
PATENT ASSIGNEE:
  Reprogen, Inc., (2612040), Suite 210, 163 West Technology Drive, Irvine,
    CA 92618, (US), (Applicant designated States: all)
INVENTOR:
  SCHNEIDER, Patrick, A., 49 Castillo, Irvine, CA 92620, (US)
  FRENCH, Cynthia, K., 14 Virgil Court, Irvine, CA 92612, (US)
  YAMAMOTO, Karen, K., 524 West Avenida de los Lobos Marinos, San Clemente,
    CA 92672, (US)
LEGAL REPRESENTATIVE:
  Bizley, Richard Edward et al (28352), Hepworth, Lawrence, Bryer & Bizley
    Merlin House Falconry Court Baker's Lane, Epping Essex CM16 5DQ, (GB)
PATENT (CC, No, Kind, Date): EP 1002136 A2 000524 (Basic)
                              WO 9963116
                                          991209
APPLICATION (CC, No, Date):
                              EP 99926150 990603; WO 99US12336 990603
PRIORITY (CC, No, Date): US 88016 P 980604
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
 LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C12Q-001/68; G01N-033/53
CITED PATENTS (WO A):
                         Y Y A A
CITED REFERENCES (WO A):
 OTA AND IGARASHI: "EXPRESSION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS
    II ANTIGEN IN ENDOMETRIC TISSUE IN PATIENTS WITH ENDOMETRIOSIS AND
    ADENOMYOSIS" FERTIL STERIL, vol. 60, no. 5, 1993, pages 834-838,
    XP000857027
 BAXEVANIS ET AL.: "PROTHYMOSIN ALPHA ENHANCES HUMAN AND MURINE MHC CLASS
    II SURFACE ANTIGEN EXPRESSION AND MESSENGER RNA ACCUMULATION"
    J.IMMUNOL., vol. 148, no. 7, 1992, pages 1979-1984, XP002125674
 HILL: "IMMUNOLOGY AND ENDOMETRIOSIS" OBSTET GYNECOL CLIN NORTH AM, vol.
    24, no. 2, 1997, pages 291-306, XP000857031
 SHARPE-TIMMS: "BASIC RESEARCH IN ENDOMETRIOIS" OBSTETRICS AND GYNECOLOGY
    CLINICS OF NORTH AMERICA, vol. 24, no. 2, June 1997 (1997-06), pages
    269-290, XP000853792
 OIKAWA ET AL.: "EXPRESSION OF GONADOTROPIN-RELEASING HORMONE AND
    PROTHYMOSIN-ALPHA MESSENGER RIBONUCLEIC ACID IN THE OVARY"
    ENDOCRINOLOGY, vol. 127, no. 5, 1990, XP000857700
 DATABASE MEDLINE Online HUMAN REPROD UPDATE, July 1998 (1998-07) OTA ET AL.: "IS ADENOMYOSIS AN IMMUNE DISEASE" XP002123261;
 No A-document published by EPO
LEGAL STATUS (Type, Pub Date, Kind, Text):
Application:
                  000524 A2 Published application without search report
Application:
                  20000202 A2 International application. (Art. 158(1))
Examination:
                  011219 A2 Date of dispatch of the first examination
                            report: 20011031
Examination:
                  000524 A2 Date of request for examination: 20000228
Application:
                  20000202 A2 International application entering European
                            phase
```

LANGUAGE (Publication, Procedural, Application): English; English;

```
DIALOG(R) File 357: Derwent Biotech Res.
(c) 2003 Thomson Derwent & ISI. All rts. reserv.
0249290 DBR Accession No.: 2000-03780
                                          PATENT
Diagnosis and treatment of %endometriosis% using %prothymosin% and
    *prothymosin* specific binding agents - protein detection method using
    DNA probe for disease diagnosis, prognosis, therapy and antisense
    oligonucleotide for gene therapy
AUTHOR: Schneider P A; French C K; Yamamoto K K
CORPORATE SOURCE: Irvine, CA, USA.
PATENT ASSIGNEE: Reprogen 1999
PATENT NUMBER: WO 9963116 PATENT DATE: 19991209 WPI ACCESSION NO.:
    2000-086987 (2007)
PRIORITY APPLIC. NO.: US 88016 APPLIC. DATE: 19980604
NATIONAL APPLIC. NO.: WO 99US12336 APPLIC. DATE: 19990603
LANGUAGE: English
ABSTRACT: A method (I) for diagnosing %endometriosis%, which consists of
    detecting elevated levels of \bar{\mbox{\$}} prothymosin\mbox{\$} gene product in a sample, is
     new. Also claimed are: a method for monitoring the progress of
     %endometriosis% by comparing the amount of %prothymosin% in 2 test
    samples, taken from the same patient at different times; a kit for
                 %prothymosin% and/or diagnosing %endometriosis% which
      detecting
     consists of a compound that binds a *prothymosin* gene product; the
                     %endometriosis% by detecting the presence of a
      diagnosis
                of
     *prothymosin* gene product in *endometriosis* tissue from a subject in
    vivo; a method for treating endometriosis which involves administering
    a DNA probe which consists of a detectable label and a ligand that
    specifically binds prothymosin, identifying an endometriotic lesion in
    situ by locating the bound label and excising the lesion; a method for
     screening for compounds that modulate the expression of %prothymosin%
      in an endometrial cell; and treating %endometriosis% by administering
     a compound which decreases %prothymosin% activity. The above may be
     useful to diagnose, prognose and treat %endometriosis% and antisense
    *prothymosin* gene oligonucleotides may be used in gene therapy. (58pp)
DESCRIPTORS: %prothymosin% det. method, DNA probe, antisense
    oligonucleotide, appl. %endometriosis% diagnosis, prognosis, therapy,
    gene therapy DNA sequence protein sequence DNA hybridization (Vol.19,
    No.7)
SECTION: PHARMACEUTICALS-Clinical Genetic Techniques; GENETIC ENGINEERING
    AND FERMENTATION-Nucleic Acid Technology (D7, A1)
           (Item 1 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.
  132021878
               CA: 132(3)21878b
                                   PATENT
  Use of prothymosin in the diagnosis and treatment of endometriosis
  INVENTOR (AUTHOR): Schneider, Patrick A.; French, Cynthia K.; Yamamoto,
Karen K.
  LOCATION: USA
  ASSIGNEE: Reprogen, Inc.
  PATENT: PCT International ; WO 9963116 A2 DATE: 19991209
  APPLICATION: WO 99US12336 (19990603) *US 88016 (19980604)
  PAGES: 59 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/68A;
GO1N-033/53B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR;
BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID;
IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT;
UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
 DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; UG; ZW; AT; BE; CH;
CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG;
CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
  SECTION:
```

1/5/4

(Item 1 from file: 357)

CA214013 Mammalian Pathological Biochemistry CA201XXX Pharmacology CA206XXX General Biochemistry IDENTIFIERS: prothymosin endometriosis diagnosis therapy drug screening DESCRIPTORS: Peritoneum... administration of diagnostic probe into; use of prothymosin in the diagnosis and treatment of endometriosis Immunoassay... competitive, use in diagnosis; use of prothymosin in the diagnosis and treatment of endometriosis Vagina... diagnostic sample comprising fluid from; use of prothymosin in the diagnosis and treatment of endometriosis Ascitic fluid... Blood... Urine... diagnostic sample comprising; use of prothymosin in the diagnosis and treatment of endometriosis Phosphorothicate oligonucleotides... Primers (nucleic acid)... diagnostic use; use of prothymosin in the diagnosis and treatment of endometriosis cDNA... DNA... Gene, animal... mRNA... RNA... encoding prothymosin; use of prothymosin in the diagnosis and treatment of endometriosis Uterus, disease... endometriosis; use of prothymosin in the diagnosis and treatment of endometriosis Uterus... endometrium, diagnostic sample comprising ectopic and/or eutopic tissue from; use of prothymosin in the diagnosis and treatment of $% \left(1\right) =\left(1\right) \left(1\right)$ endometriosis Drug screening ... for compds. that regulate prothymosin expression/activity; use of prothymosin in the diagnosis and treatment of endometriosis Test kits... for detection of prothymosin; use of prothymosin in the diagnosis and treatment of endometriosis Radiation detectors... Geiger, use in diagnosis; use of prothymosin in the diagnosis and treatment of endometriosis immobilized, encoding prothymosin; use of prothymosin in the diagnosis and treatment of endometriosis Diagnosis... immunodiagnosis; use of prothymosin in the diagnosis and treatment of endometriosis Oligonucleotides... labeled, diagnostic use; use of prothymosin in the diagnosis and treatment of endometriosis Diagnosis... mol.; use of prothymosin in the diagnosis and treatment of endometriosis Imaging... NMR, use in diagnosis; use of prothymosin in the diagnosis and treatment of endometriosis Immunoassay.. non-competitive, use in diagnosis; use of prothymosin in the diagnosis and treatment of endometriosis Peptide nucleic acids... oligonucleotides comprising, diagnostic use; use of prothymosin in the diagnosis and treatment of endometriosis Drug delivery systems... solns., i.p., administration of drugs via; use of prothymosin in the

that regulate prothymosin expression/activity; use of prothymosin in

diagnosis and treatment of endometriosis

Drugs...

the diagnosis and treatment of endometriosis Mass spectrometry... use in detecting prothymosin; use of prothymosin in the diagnosis and treatment of endometriosis Antibodies... Cameras... Nucleic acid amplification (method)... Paramagnetic materials... Radionuclides... use in diagnosis; use of prothymosin in the diagnosis and treatment of endometriosis Antisense DNA... Ribozymes... use in regulating prothymosin expression; use of prothymosin in the diagnosis and treatment of endometriosis use of prothymosin in the diagnosis and treatment of endometriosis Nucleotides, uses.. 2'-O-methyl; oligonucleotides comprising; use of prothymosin in the diagnosis and treatment of endometriosis CAS REGISTRY NUMBERS: 993-13-5 22638-09-1 41744-81-4 oligonucleotides comprising, diagnostic use; use of prothymosin in the diagnosis and treatment of endometriosis 251922-35-7 251922-36-8 251922-37-9 unclaimed nucleotide sequence; use of prothymosin in the diagnosis and treatment of endometriosis 125524-66-5 unclaimed protein sequence; use of prothymosin in the diagnosis and treatment of endometriosis 89964-14-7P use of prothymosin in the diagnosis and treatment of endometriosis ? logoff 17may03 13:44:04 User208652 Session D492.6 \$0.67 0.142 DialUnits File349 \$10.90 2 Type(s) in Format 5 \$10.90 2 Types Estimated cost File349 \$11.57 \$0.28 0.061 DialUnits File348 \$3.15 1 Type(s) in Format 2 \$3.15 1 Types \$3.43 Estimated cost File348 \$0.55 0.030 DialUnits File357 \$3.23 1 Type(s) in Format 5 \$3.23 1 Types \$3.78 Estimated cost File357 \$1.02 0.081 DialUnits File399 \$2.75 1 Type(s) in Format 5 \$2.75 1 Types \$3.77 Estimated cost File399 OneSearch, 4 files, 0.314 DialUnits FileOS \$1.40 TELNET \$23.95 Estimated cost this search \$39.76 Estimated total session cost 2.349 DialUnits Logoff: level 02.14.01 D 13:44:04